Clinical Study
Eye (2005) 19, 535–539. doi:10.1038/sj.eye.6701537 Published online 21 May 2004
Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients
Financial interest: none
Industry sponsorship: none
P Aragona1, A Stilo1, F Ferreri1 and M Mobrici1
1Department of Surgical Science, Section of Ophthalmology, University of Messina, Messina, Italy
Correspondence: P Aragona, Viale Boccetta, 70 Messina I-98122, Italy. Tel: +39 090 343184; Fax: +39 090 2924819; E-mail: paragona@unime.it
Received 11 June 2003; Revised 20 February 2004; Accepted 20 February 2004; Published online 21 May 2004.
Abstract
Aim and purpose
To evaluate the effects of two NSAIDs on corneal sensitivity and ocular surface in Sjögren's syndrome (SS) patients.
Methods
In all, 20 SS patients with epithelial corneal defects, were randomly divided into two groups: group 1 (10 females, age 35–63 years), treated with 0.1% indomethacin, one drop three times a day; group 2 (nine females, one male, age 38–65 years) treated with 0.1% diclofenac, at the same regimen. No systemic NSAIDs were allowed. Use of tear substitute was allowed. Corneal sensitivity, corneal staining, BUT, and ocular discomfort, were evaluated before and after 15, 30 days of treatment and 7 days after NSAID discontinuation. For statistical analysis, the Student's t-test and Mann–Whitney U test were used.
Results
Both groups showed at day 30 a statistically significant reduction of corneal sensitivity (P<0.05), although the diclofenac-treated group showed a statistically significant lower sensitivity if compared to the indomethacin-treated group (P<0.05). Corneal fluorescein score showed a statistically significantly worst alteration in group 2, 7 days after the discontinuation of the therapy (P=0.02). The ocular discomfort score was statistically significantly reduced in both groups starting from day 15 (P<0.05).
Discussion
The results indicate that NSAIDs can be useful in resolving symptoms of ocular discomfort in SS patients. However, they should be used with caution and under close monitoring, and the treatment should be promptly discontinued if corneal epithelial defects develop or worsen during treatment.
Keywords:
indomethacin, diclofenac, corneal sensitivity, corneal epithelial defects, Sjögren's syndrome
